Thiele J, Kvasnicka H, Gianelli U, Arber D, Tefferi A, Vannucchi A
Blood Cancer J. 2025; 15(1):31.
PMID: 40038244
PMC: 11880409.
DOI: 10.1038/s41408-025-01235-7.
Tyndall H, Worobetz L, Nicholson M
J Hematol. 2024; 13(4):158-163.
PMID: 39247061
PMC: 11379051.
DOI: 10.14740/jh1297.
Jayaraman M, Vishali S, Grace Priyadarshini S
Cureus. 2024; 16(3):e56120.
PMID: 38618321
PMC: 11015355.
DOI: 10.7759/cureus.56120.
Mahmud M, Vasireddy S, Gowin K, Amaraneni A
Int J Mol Sci. 2023; 24(24).
PMID: 38139212
PMC: 10744078.
DOI: 10.3390/ijms242417383.
Masarova L, Bose P, Pemmaraju N, Daver N, Sasaki K, Chifotides H
Cancer. 2023; 129(18):2828-2835.
PMID: 37243913
PMC: 11831606.
DOI: 10.1002/cncr.34851.
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.
Yan X, Xu Z, Zhang P, Sun Q, Jia Y, Qin T
Blood Cancer J. 2023; 13(1):56.
PMID: 37080954
PMC: 10119377.
DOI: 10.1038/s41408-023-00829-3.
Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis.
Luther M, Henes F, Zabelina T, Massoud R, Janson D, Wolschke C
Bone Marrow Transplant. 2023; 58(7):755-761.
PMID: 37002409
DOI: 10.1038/s41409-023-01968-8.
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression.
Kong T, Laranjeira A, Yang K, Fisher D, Yu L, Poittevin De La Fregonniere L
Nat Cancer. 2022; 4(1):108-127.
PMID: 36581736
PMC: 11288645.
DOI: 10.1038/s43018-022-00486-8.
Extramedullary hematopoiesis causing spinal cord compression in polycythemia vera: A case report and literature review.
Cailleteau A, Agbetsivi K, Guimas V, Supiot S, Ollivier L
Clin Transl Radiat Oncol. 2022; 38:43-46.
PMID: 36353654
PMC: 9638719.
DOI: 10.1016/j.ctro.2022.09.009.
Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world.
Zhang X, Wang F, Yu J, Jiang Z
Front Oncol. 2022; 12:971082.
PMID: 36276150
PMC: 9585239.
DOI: 10.3389/fonc.2022.971082.
Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis.
Hasan K, Elmeshhadany A, Shabila N
Sultan Qaboos Univ Med J. 2022; 22(3):393-399.
PMID: 36072080
PMC: 9423752.
DOI: 10.18295/squmj.8.2021.110.
Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.
Battukh N, Ali E, Yassin M
Acta Biomed. 2022; 92(6):e2021478.
PMID: 35075062
PMC: 8823556.
DOI: 10.23750/abm.v92i6.12350.
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis.
Genovese E, Mirabile M, Rontauroli S, Sartini S, Fantini S, Tavernari L
Antioxidants (Basel). 2022; 11(1).
PMID: 35052617
PMC: 8772737.
DOI: 10.3390/antiox11010113.
Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A, Gangat N, Pardanani A, Crispino J
Cancer Res. 2021; 82(5):749-763.
PMID: 34911786
PMC: 9306313.
DOI: 10.1158/0008-5472.CAN-21-2930.
Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice.
Saito N, Yamauchi T, Kawano N, Ono R, Yoshida S, Miyamoto T
Int J Hematol. 2021; 115(2):198-207.
PMID: 34773575
PMC: 8905546.
DOI: 10.1007/s12185-021-03239-y.
The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms.
Lanzarone G, Olivi M
Medicina (Kaunas). 2021; 57(8).
PMID: 34441019
PMC: 8398709.
DOI: 10.3390/medicina57080813.
Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.
Nann D, Fend F
Cancers (Basel). 2021; 13(14).
PMID: 34298741
PMC: 8303289.
DOI: 10.3390/cancers13143528.
PPARγ agonists promote the resolution of myelofibrosis in preclinical models.
Lambert J, Saliba J, Calderon C, Sii-Felice K, Salma M, Edmond V
J Clin Invest. 2021; 131(11).
PMID: 33914703
PMC: 8159700.
DOI: 10.1172/JCI136713.
The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.
Belcic Mikic T, Pajic T, Zver S, Sever M
Int J Mol Sci. 2021; 22(7).
PMID: 33806036
PMC: 8038093.
DOI: 10.3390/ijms22073371.
Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy.
Piasecki A, Leiva O, Ravid K
Arch Stem Cell Ther. 2021; 1(1):23-27.
PMID: 33738462
PMC: 7968867.
DOI: 10.46439/stemcell.1.005.
